XNYS · Diagnostics & Research
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$266.42-1.12%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
59/100
Positive
Score components
TickerWhale View
IQVIA Holdings scores 59 out of 100 overall, which we rate positive. Technical is its strongest area and Quality & growth its weakest.
What helps
- Technical
- Valuation
- Sentiment Signal
What to watch
- Quality & growth
- Risk
Quality & growth
30%33Weak
- Revenue growth 8.2%
- EPS growth 16.6%
Valuation
25%64Positive
- P/E 32.4
- EV/Sales 3.5
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
#270 by market cap in our coverage · ~94,000 employees · Listed 2013-05-09 · www.iqvia.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#55 / 139sector rank by TickerWhale Score
TickerWhale Score 59 vs sector average 55.1 (+3.9)
Revenue growth (industry)Top 53%
Gross margin (industry)Top 82%
Return on equity (industry)Top 29%
P/E (industry)Cheaper than 64%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
96/100Strong vs universe
Ranks 96th of 100 covered names on our technical composite — the composite itself scores 78/100 · 25% of the TickerWhale Score
Classic chart indicators
Buy
3 buy · 2 sell · 3 neutral of 8 votes
TickerWhale rates IQV's technical setup strong — 96th percentile of the covered universe. Classic chart indicators lean buy, pointing the same way.
Moving averages
9 / 9constructive
- vs 200-day+30.8%
- vs 50-day+10.4%
Momentum
Mixed
- RSI (14)62 · neutral
- Stochasticsell
- CCIneutral
- Williams %Rneutral
Trend
Mixed
- ADX (14) trend strength32· trending
- MACD (12,26,9)sell(histogram -0.941)
How the classic verdict is reached
Moving averages (9) agree on buy — 9 buy vs 0 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 2 sell · 3 neutral.
Result — 3 buy vs 2 sell of 8 votes = Buy. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)32.4
- P/S (TTM)2.6
- P/B7.2
- EV/EBITDA—
- EV/Sales3.5
- PEG1.95
Profitability & returns
- Gross margin33.0%
- Net margin8.1%
- ROE22.2%
- Debt/Equity2.59
Growth
- Revenue growth (YoY)8.2%
- EPS growth (YoY)16.6%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $44.6B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IQVCurrentIQVIA Holdings | 59 | 78 | 32.4 | — | 7.2 | 3.5 | $266.42 | -1.12% | +8.2% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.